Strong Start for Biotech and Pharma Mergers and Acquisitions in 2025: Can it be Sustained?

After spending close to a week in San Francisco for the yearly JPMorgan Health Care Conference, the largest gathering in the U.S. for biotech and pharma professionals, investors, and analysts, it is good to be back in New York City. The event was a hub of activity and discussions surrounding the incoming Trump administration, updates on business outlooks, drug portfolios, and increased security measures.

It was a week filled with significant developments that did not stop even after the conference concluded on Thursday. The Biden administration revealed the next 15 drugs eligible for Medicare price negotiations, featuring Novo Nordisk’s Ozempic and Wegovy for obesity. Meanwhile, several deals were announced during the week, setting the stage for an eventful year in the pharma sector in 2025.

The M&A scene seems to have kicked off on a positive note this year, with some promising transactions already in the works. Johnson & Johnson’s proposed acquisition of Intra-Cellular Therapies for $14.6 billion stands out as a significant deal, marking one of the biggest transactions in the pharmaceutical industry since 2023. In addition to this, several other companies like GSK, Eli Lilly, and lesser-known radiopharmaceutical firms have also made smaller deals, hinting at an active year ahead.

According to Stifel analyst Tim Opler, the flurry of activity with five deals in just a business day and a half indicates a shift towards a more vibrant M&A landscape compared to the previous year. The EY M&A Firepower report noted that 2024 saw a trend of smaller and strategic deals in the pharma industry, focusing on lower-priced products and early-stage ventures that held potential for significant returns in the future.

While 2025 has begun with a surge in transactions, the report warns about potential constraints that could impact M&A activity moving forward. Biopharmaceutical companies are grappling with margin pressures, dampening the appetite for large-scale spending. Additionally, the market premiums for prime acquisition targets are at elevated levels, posing challenges for companies eyeing big buyouts.

Major pharma players have recognized the significance of strategic deals over mega transactions. J&J’s CEO, Joaquin Duato, highlighted the value derived from smaller deals and partnerships, with the company’s focus on creating value through scale. However, despite the cautious approach, there are strong incentives for a return to dealmaking, including the industry’s substantial dealmaking capabilities totaling $1.3 trillion and the impending patent expirations that could impact revenues.

Looking ahead, it remains to be seen how these factors will shape the M&A landscape in the pharma sector as the year progresses. With various dynamics at play, including regulatory changes and market pressures, the industry is poised for an eventful year in dealmaking and strategic partnerships.